Evidence map›Paper›PMID 27870591›Full record

ArticleHuman vaccines & immunotherapeutics2017

Human transcriptome response to immunization with live-attenuated Venezuelan equine encephalitis virus vaccine (TC-83): Analysis of whole blood.

Rebecca A Erwin-Cohen, Aimee I Porter, Phillip R Pittman, Cynthia A Rossi, Luis DaSilva

Registry-linked trialAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04934111 (A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04934111 phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2021 to 2022Enrolled42ConditionsCOVID-19ArmsLNP-nCOV saRNA-02 Vaccine
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.Current topics in microbiology and immunology · 2022
    Article
  3. Review
  4. Genetic control of alphavirus pathogenesis.Mammalian genome : official journal of the International Mammalian Genome Society · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rebecca A Erwin-Cohena Virology Division, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA.
Aimee I Portera Virology Division, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA.
Phillip R Pittmanb Division of Medicine, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA.
Cynthia A Rossic Diagnostics Systems Division, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA.
Luis DaSilvad Center for Aerobiological Sciences, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naïve individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.

Indexed as

Gene Expression ProfilingAdultAnimalsEncephalitis, ViralEncephalitis Virus, Venezuelan EquineEncephalomyelitis, Venezuelan EquineHealthy VolunteersHumansMaleMiddle AgedVaccines, AttenuatedViral VaccinesYoung AdultVaccines, AttenuatedViral Vaccinesbiomarkergene expressionmicroarraytranscriptomevaccinationVenezuelan equine encephalitis virus

Identifiers

PMID27870591
PMCPMC5287313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.